Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo.
Inflammatory chemokines recruit various populations of immune cells that initiate and maintain the inflammatory response against foreign Ags. Although such a response is necessary for the elimination of the Ag, the inflammation has to be eventually resolved in a healthy organism. Neuropeptides such as vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP), released after antigenic stimulation, contribute to the termination of an inflammatory response primarily by inhibiting the production of proinflammatory cytokines. Here we investigated the effects of VIP and PACAP on chemokine production. We report that VIP and PACAP inhibit the expression of the macrophage-derived CXC chemokines macrophage inflammatory protein-2 and KC (IL-8), and of the CC chemokines MIP-1alpha, MIP-1beta, monocyte chemoattractant protein 1, and RANTES in vivo and in vitro. The inhibition of chemokine gene expression correlates with an inhibitory effect of VIP/PACAP on NF-kappaB binding and transactivating activity. The VIP/PACAP inhibition of both chemokine production and of NF-kappaB binding and transactivating activity is mediated through the specific VIP receptor VPAC1, and involves both cAMP-dependent and -independent intracellular pathways. In an in vivo model of acute peritonitis, the inhibition of chemokine production by VIP/PACAP leads to a significant reduction in the recruitment of polymorphonuclear cells, macrophages, and lymphocytes into the peritoneal cavity. These findings support the proposed role of VIP and PACAP as key endogenous anti-inflammatory agents and describe a novel mechanism, i.e., the inhibition of the production of macrophage-derived chemokines.
Delgado
M
M
Department of Biological Sciences, Rutgers University, 101 Warren Street, Newark, NJ 07102, USA.
Ganea
D
D
D000208:Acute Disease; D000818:Animals; D002460:Cell Line; D002464:Cell Migration Inhibition; D002478:Cells, Cultured; D018925:Chemokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics; D019742:Chemokines, CC / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D019743:Chemokines, CXC / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000276:immunology; D007274:Injections, Intraperitoneal; D016753:Interleukin-10 / Q000502:physiology; D007424:Intracellular Fluid / Q000276:immunology; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000494:pharmacology*; D017737:Macrophages, Peritoneal / Q000276:immunology* / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D009479:Neuropeptides / Q000008:administration & dosage* / Q000494:pharmacology*; D010538:Peritonitis / Q000276:immunology / Q000473:pathology; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D011485:Protein Binding / Q000276:immunology; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D018005:Receptors, Vasoactive Intestinal Peptide / Q000502:physiology; D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I; D015398:Signal Transduction / Q000276:immunology; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage* / Q000494:pharmacology*
C495402:Adcyap1 protein, mouse; D018925:Chemokines; D019742:Chemokines, CC; D019743:Chemokines, CXC; D008070:Lipopolysaccharides; D016328:NF-kappa B; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012333:RNA, Messenger; D018005:Receptors, Vasoactive Intestinal Peptide; D051238:Receptors, Vasoactive Intestinal Polypeptide, Type I; D016753:Interleukin-10; D014660:Vasoactive Intestinal Peptide